



CARDIAWAVE




**HealthTech
AWARD** 2020

CARDIAWAVE

Maurice Delplanque, COO


Apr, 2021



2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited


Calcified Aortic Stenosis (CAS)



- **Third-most frequent** cardiovascular disease
- Progression with **age**
- Severe CAS is a **life-threatening** condition... **2-3** years life expectancy
- **10M patients** affected in western countries
- 16% severe symptomatic are not eligible to surgery
- **400,000** patients left **with no medical solution**

**Cardiawave has been created
to treat these patients**

Unique Non-invasive ultrasound therapy solution



- Focused ultrasound \neq HIFU
- Very intense and very short pulses ($10 \mu\text{s}$)
- Clouds of microscopic cavitation bubbles
- When cavitation bubbles implode, they produce shock waves

micro-fragmentation of calcium embedded in valve leaflets soften the tissues


Valvosoft : a unique combination of three innovative technologies



Pulsed Cavitation Ultrasound... energy

Ultrasound Image guidance & monitoring... precision and safety

Cobotics... ergonomics



- Non-invasive
- Light or no sedation
- 1 hour of therapy
- Outpatient (ambulatory)

Cardiawave Team



Benjamin BERTRAND
CEO, Cofunder
& Chairman of the board



Dr René SPAARGAREN
Chief Medical Officer



Luc MORISSET
Quality and Regulatory
Affairs Director



Maurice DELPLANQUE
Chief Operative Officer
Chief Technical Officer




INNOVATION 2030
CONCOURS MONDIAL D'INNOVATION



Institut Langevin
ONDES ET IMAGES





Hôpital européen Georges-Pompidou



Clinical study results




- Multicentric « First in Man » (FR, NL, RS)
- Indication: patients not eligible to valve replacement
- 28 patients treated
- No procedure or device related major adverse events at 12 months
- Improvement of anatomical and hemodynamics and QoL for a majority of patients
- Results published in *Circulation*



Next steps



- Launch CE marking study in Eur. and an Early Feasibility Study in the US
- Capital increase in Q4 2021, Q1 2022
- In the future, expand current indication by treating preventively moderate patients **+3M patients**
 - slow down progression of the disease
 - delay valve replacement



2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited